Effects of alendronate on osteopenic postmenopausal Chinese women

Bone

Volumn 27, Issue 5, 2000, Pages 681-685

  Yen, M L ^a   Yen, B L ^a   Jang, M H ^b   Hsu, S H J ^a   Cheng, W C ^a   Tsai, K S ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bone mineral density (BMD); Deoxypyridinoline (Dpd); Hip; N telopeptide of type I collagen (NTx); Spine

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLLAGEN TYPE 1; CREATININE; DEOXYPYRIDINOLINE; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; CHINA; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; TAIWAN;

EID: 0033755740     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00384-7     Document Type: Article

References (31)

1. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
2. Dose-response relationships for alendronate treatment in osteoporotic elderly women
3. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
4. Bone density at various sites for prediction on hip fractures
5. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
6. The future of hip fractures in the United States: Numbers, costs and potential effects of postmenopausal estrogen
7. Treatment with alendronate prevents fractures in women at highest risk: Results from the fracture intervention trial
8. Bisphosphonates in osteoporosis: An introduction
9. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
10. A specific immunoassay for monitoring human bone resorption: Quantitation of type A collagen cross-linked N-telopeptides in urine
11. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women
12. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
13. The diagnosis of osteoporosis
14. Prevention of nonvertebral fractures by alendronate: A meta-analysis
15. Mortality and morbidity after hip fractures
16. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
17. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
18. Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial
19. Long term fracture prediction by bone mineral density assessed at different skeletal sites
20. Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption
21. Bisphosphonates in the treatment of metabolic bone diseases
22. Long-term effects of treatment course with oral alendronate of postmenopausal osteoporosis
23. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat
24. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group
25. Epidemiology of osteoporosis in Taiwan
26. Bone densitometry of proximal femur in Chinese subjects: Gender differences in bone mass and bone areas
27. The effect of bone area on spine densitometry in Chinese men and women in Taiwan
28. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women
29. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
30. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo
31. Skeletal benefits of two years alendronate treatment are similar for early postmenopausal Asian and Caucasian women